It is the established policy of The Drug, Chemical & Associated Technologies Association and all of its operating committees to conduct their operations in strict compliance with the antitrust laws of the United States of America. The DCAT antitrust policy prohibits any discussions which constitute or imply any agreement or understanding concerning:
- prices, discounts or terms of conditions or sale;
- profits, profit margins or cost data;
- market shares, sales territories or markets;
- allocation of customers or territories;
- selection, rejection or termination of customers or suppliers;
- restricting the territory or markets in which a company may resell products;
- restricting the customers to whom a company may sell; or
- any matter which is inconsistent with the proposition that each member company of DCAT must exercise its independent business judgment in pricing its service or products, dealing with its customers and suppliers and choosing the markets in which it will compete.
Meetings of the DCAT Executive Committee, Board of Directors and all standing committees shall be conducted pursuant to agendas distributed to attendees and minutes of these meetings shall be distributed to attendees promptly. Actions taken at these meetings will be reported to the membership on a regular basis.